Publication
Survival analysis of the randomised phase III GeparOcto trial comparing neoadjuvant chemotherapy of intense dose-dense epirubicin, paclitaxel, cyclophosphamide versus weekly paclitaxel, liposomal doxorubicin (plus carboplatin in triple-negative breast cancer) for patients with high-risk early breast cancer
Journal Paper/Review - Nov 17, 2021
Schneeweiss Andreas, Blohmer Jens-Uwe, Fasching Peter A, Solbach Christine, Schmutzler Rita K, Huober Jens, Rhiem Kerstin, Nekljudova Valentina, Lübbe Kristina, Loibl Sibylle, Jackisch Christian, Untch Michael, Link Theresa, Michel Laura L, Möbus Volker, Tesch Hans, Klare Peter, Hahnen Eric, Denkert Carsten, Kast Karin, Pohl-Rescigno Esther, Hanusch Claus, GBG and AGO-B
Schneeweiss, Andreas
Michel, Laura L
Möbus, Volker
Tesch, Hans
Klare, Peter
Hahnen, Eric
Denkert, Carsten
Kast, Karin
Pohl-Rescigno, Esther
Hanusch, Claus
Link, Theresa
Untch, Michael
Jackisch, Christian
Blohmer, Jens-Uwe
Fasching, Peter A
Solbach, Christine
Schmutzler, Rita K
Huober, Jens
chief physicianBrustzentrum St.Gallen, Medizinische Onkologie und Hämatologie · Dept. IV, Dept. I